LRP8 is overexpressed in estrogen-negative breast cancers and a potential target for these tumors.
HER2
LRP8
apoptosis
targeted therapy
triple-negative breast cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
02
08
2018
revised:
19
10
2018
accepted:
23
11
2018
pubmed:
24
12
2018
medline:
4
3
2020
entrez:
22
12
2018
Statut:
ppublish
Résumé
Triple-negative breast cancer (TNBC) is the breast cancer subtype with the worst prognosis. New treatments improving the survival of TNBC patients are, therefore, urgently required. We performed a transcriptome microarray analysis to identify new treatment targets for TNBC. We found that low-density lipoprotein receptor-related protein 8 (LRP8) was more strongly expressed in estrogen receptor-negative breast tumors, including TNBCs and those overexpressing HER2, than in luminal breast tumors and normal breast tissues. LRP8 depletion decreased cell proliferation more efficiently in estrogen receptor-negative breast cancer cell lines: TNBC and HER2 overexpressing cell lines. We next focused on TNBC cells for which targeted therapies are not available. LRP8 depletion induced an arrest of the cell cycle progression in G1 phase and programmed cell death. We also found that LRP8 is required for anchorage-independent growth in vitro, and that its depletion in vivo slowed tumor growth in a xenograft model. Our findings suggest that new approaches targeting LRP8 may constitute promising treatments for hormone-negative breast cancers, those overexpressing HER2 and TNBCs.
Identifiants
pubmed: 30575334
doi: 10.1002/cam4.1923
pmc: PMC6346259
doi:
Substances chimiques
LDL-Receptor Related Proteins
0
low density lipoprotein receptor-related protein 8
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
325-336Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Oncotarget. 2017 Jan 3;8(1):1913-1924
pubmed: 27765921
J Lipid Res. 2017 Jun;58(6):1036-1043
pubmed: 28292942
Oncotarget. 2017 Jul 11;8(28):46652-46662
pubmed: 28445140
J Cell Biochem. 2012 Jan;113(1):13-8
pubmed: 21898546
Breast Cancer Res. 2008;10(6):R101
pubmed: 19055754
PLoS One. 2013 May 20;8(5):e63712
pubmed: 23700430
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Br J Cancer. 2010 May 25;102(11):1555-77
pubmed: 20502460
Oncotarget. 2015 Sep 29;6(29):26560-74
pubmed: 26387133
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Cell. 2012 Nov 21;151(5):1068-82
pubmed: 23142051
J Bone Miner Res. 2012 Oct;27(10):2065-74
pubmed: 22589174
Lancet. 2017 Mar 18;389(10074):1134-1150
pubmed: 27865536
Oncogenesis. 2017 Apr 3;6(4):e310
pubmed: 28368389
Oncotarget. 2017 Aug 16;8(42):73329-73344
pubmed: 29069872
Lancet. 2017 Jun 17;389(10087):2430-2442
pubmed: 27939063
PLoS One. 2015 Apr 07;10(4):e0122333
pubmed: 25848952
PLoS One. 2016 Dec 22;11(12):e0167397
pubmed: 28005906
Cancer Res. 2013 Jan 15;73(2):813-23
pubmed: 23144294
Hum Mol Genet. 2005 Feb 15;14(4):475-82
pubmed: 15615770
Physiol Rev. 2017 Jul 1;97(3):1211-1228
pubmed: 28615463
Nat Genet. 2003 Nov;35(3):270-6
pubmed: 14578885
Oncotarget. 2018 Apr 27;9(32):22586-22604
pubmed: 29854300
Mol Oncol. 2015 Oct;9(8):1580-98
pubmed: 26004086
Mol Cells. 2014 Nov;37(11):767-76
pubmed: 25358504
Cell. 2018 Feb 8;172(4):825-840.e18
pubmed: 29336888
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Oncotarget. 2016 Jan 19;7(3):2555-71
pubmed: 26700623
Cancer Med. 2019 Jan;8(1):325-336
pubmed: 30575334
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925